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A B S T R A C T
Contagious bovine pleuropneumonia (CBPP), a severe respiratory disease of cattle caused
by Mycoplasma mycoides subsp. mycoides (Mmm) is endemic in many African countries due
to fragmented veterinary services and the lack of an efﬁcient vaccine and sensitive
diagnostics. More efﬁcient tools to control the disease are needed, but to develop the tools,
a better understanding of host–pathogen interactions is necessary. The aim of this study
was to characterize the kinetics of the humoral immune response against 65 Mmm surface
antigens for an extended period in cattle that survived a primary infection with Mmm. We
describe clinical and haematological outcomes, and dissect the humoral immune response
over time, to speciﬁc antigens and compared the antibody responses between different
pathomorphological outcomes.
No antigen-speciﬁc antibodies correlating with protection were identiﬁed. Interest-
ingly we found that animals that developed Mycoplasma-containing sequestra had
signiﬁcantly higher antibody levels against proteins comprising the surface proteome than
the animals that cleared Mycoplasma from their lungs. Based on these data we suggest that
high antibody titres might play a role in the establishment of pathomorphological changes,
such as vasculitis, which should be investigated in future studies. Beneﬁcial antibody
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Contagious bovine pleuropneumonia (CBPP) caused by
Mycoplasma mycoides subsp. mycoides (Mmm) is a severe
respiratory disease of cattle that is widespread in sub-
Saharan Africa. Mmm shows very little sequence diversity
and is a member of the so called ‘Mycoplasma mycoides
cluster’ encompassing several ruminant pathogens whose
ancestry coincides with the domestication of ruminants
(Fischer et al., 2012). CBPP can cause acute or subacute
symptoms that may progress into a chronic stage, death or
recovery. Acute stages of the disease are characterized by
fever, pleural effusion, severe respiratory distress and the
characteristic cough (Thiaucourt et al., 2004), with a
mortality rate reaching up to 60% or higher in naı¨ve
populations (Huebschle et al., 2006).
Currently the control of CBPP in sub-Saharan Africa
mainly relies on live vaccines (T144 and T1SR) with low
efﬁcacy, short duration of immunity, occasional severe side
effects and the need for a cold chain (Tulasne et al., 1996).
The extracellular location of the pathogen suggests a
paramount role of antibodies in controlling the disease, but
it does not exclude a role for cellular immunity as
described elsewhere (Totte et al., 2008, 2013). Therefore,
a thorough characterization of the bovine humoral
immune response is likely to contribute to the develop-
ment of better control measures. Identiﬁcation of antigens
important for protective immunity, namely those antigens
to which antibody responses either play a role in clearing
infections or in any other way reduce the severity of
disease, would be very helpful since they could be used as
candidate vaccine targets. Data regarding host serological
responses and its association with disease outcome is still
scanty, possibly due to the difﬁculty in standardizing and
reproducing the challenge model.
Recently a bead-based array assay was developed that
enables simultaneous characterization of the host humoral
immune response against more than 60 different myco-
plasma antigens (Hamsten et al., 2009, 2010).
Therefore, the aim of this study was to characterize the
kinetics of the humoral immune response against part of
the surface proteome of Mmm for an extended period of
234 days post infection (dpi) in cattle that survived a
primary infection with Mmm. The same bead-based array
assay described above was used in our study. Correlations
between antibody speciﬁcities, treatment and disease
outcome were assessed.
2. Materials and methods
2.1. Ethical considerations
All protocols of this study were designed and performed
in strict accordance with the Kenyan legislation for animal
animal care and use committee (IACUC reference number
2008.08).
2.2. Animal experiment setup
Seven Boran cattle (Bos indicus), randomly selected from
the ILRI ranch in Kapiti (CBPP free-region in Kenya) aged
21–23 months at the time of infection, were kept at the ILRI
farm in Nairobi on a double fenced grassland with shelter
for more than 200 days prior to the experimental infection.
Prior to transfer to ILRI Nairobi, all animals tested
serologically negative for CBPP, East Coast Fever and
trypanosomiasis as done before (Sacchini et al., 2011).
Additionally, the animals were dewormed 90 days and 7
days before infection and vaccinated against lumpy skin
disease, anthrax/blackleg (Blanthax vaccine, Cooper K-
Brands Ltd, Kenya) and foot and mouth disease as described
previously (Sacchini et al., 2011). Seven days before the
experimental infection all animals were transferred to the
animal biological safety level two facility (ABSL-2) where
they were kept in one room with the ability to move freely
and having access to food and water ad libitum. The body
weight of the animals ranged from 200 to 300 kg.
Mycoplasma mycoides subsp. mycoides Afade´ cultures
were prepared as described previously (Sacchini et al.,
2011), aliquoted and stored at 80 8C ﬁve months prior to
experimental infection. To conﬁrm that no signiﬁcant
viability had been lost during storage, we determined the
cfu count prior to infection. On the day of infection (day 0)
the animals were sedated using 0.5 cc of 2% Xylacine
solution/per animal and were then inoculated endotra-
cheally in lateral recumbency using a bronchoscope with
50 ml Mmm culture (1010 colony forming units/animal)
followed by 20 ml of a 1.5% heated agar solution and 30 ml
phosphate buffered saline (PBS) as described previously
(Sacchini et al., 2011).
The health status of the animals including the body
temperature was monitored daily from seven days prior to
infection until end of the study. We measured the body
temperature by using a digital thermometer that was
inserted about 5 cm into the rectum. Rectal temperatures
exceeding 39 8C were considered as fever. Animals with
severe clinical symptoms (fever > 40 8C for 3 consecutive
days, breathing distress, recumbency and inappetence)
were treated with a single intramuscular injection
(6000 mg/animal) of long-acting oxytetracycline (Alamy-
cin LA300, Norbrook, United Kingdom). Animals were bled
starting two weeks prior to infection, once a week up to
seven weeks post infection (pi) and bled fortnightly
thereafter.
2.3. Necropsy
At 232–234 dpi animals were euthanized via stunning
speciﬁcities and cellular immune responses need to be identiﬁed in order to foster the
development of an improved vaccine in the future.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).using a captive bolt, followed by exsanguination. Theexperimentation and were approved by the institutional
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afuss, 1988).
 Haematology
White blood cell count (WBC), lymphocytes, mono-
es, granulocytes, red blood cell count (RBC), haemoglo-
 (Hb), haematocrit (Hct), mean corpuscular
moglobin (MCH), mean corpuscular haemoglobin
centration (MCHC), mean corpuscular volume (MCV),
dom distribution width (RDW) for red blood cells,
teletcrit (Pct) and platelet distribution width (PDW)
re measured using the MS4 full automatic haematology
nter from Melet-Schloesing (France) according to
dors protocol at the veterinary faculty Nairobi.
 Microbiology
Bio banked frozen specimens (sequestra, lung tissue
wing pathomorphological lesions, mediastinal lymph
es and pleural ﬂuid) were used for isolation of
coplasma mycoides subsp. mycoides, Pasteurella spp.
 Mannheimia spp. Mycoplasma liquid media from
coplasma experience Ltd. were used for isolation of
coplasma. A PCR targeting the gene lppq was used to
ﬁrm the presence of Mmm (Abdo et al., 2000).
Additionally, specimens from diseased lung were
ead on blood agar plates and on selective agar plates
Pasteurella spp. and Mannheimia spp. (Oxoid, Wesel,
many). The plates were incubated at 37 8C for 24–48 h.
btful colonies were tested for a positive oxidase
ction (Oxidase reagent, SIFIN, Berlin, Germany) and
re ﬁnally tested using Matrix-assisted Laser Desorption/
ization Time of Flight (MALDI-TOF) mass spectrometric
lysis (Bruker, Billerica, USA).
 Multiplex real-time PCR assay for the detection of M.
coides subsp. mycoides in lung tissue
A multiplex real-time PCR assay targeting the genes
oding a hypothetical transmembrane protein
C_0136) and LppQ (MSC_1046) was used to detect
m in lung specimens showing pathomorphological
ons as described previously (Schnee et al., 2011).
 Serology
Pre and post infection sera from all animals were
lysed for antibodies to bovine herpes virus 1 (BHV-1),
ine respiratory syncytial virus (BRSV), bovine respira-
 parainﬂuenza-3 (PI-3), bovine herpes virus 4 (BHV-4)
 Coxiella burnetii as described previously (Sacchini et al.,
1).
 Assessment of humoral immune responses using a bead-
ed array assay
The IgG responses against 65 recombinant mycoplasma
teins were investigatedin sera collected at32 time points
 the seven CBPP infected animals using a bead-based
y assay as previously described (Hamsten et al., 2009).
2.9. Statistical analysis
Haematological parameters were categorized into three
stages using pyrexia as an initial indication of infection: (i)
pre-infection stage (13 to 0 dpi), (ii) acute stage (1–22
dpi, ﬁrst recorded fever to end of initial fever episode for all
animals) and (iii) post-acute stage (23–234 dpi).
Differences between (i) pre-infection and acute stage
and (ii) pre-infection and post-acute stage were investi-
gated using a Wilcoxon Matched-Pairs (Signed Rank) non-
parametric test (Siegel, 1956) deﬁning p  0.05 to be
signiﬁcant. To evaluate differences between treated/non-
treated animals and the presence/absence of sequestra on
haematological parameters a random permutation exact
test (non-parametric equivalent to a 1 or 2-sample t-test as
small number of observations) was performed for each
parameter, deﬁning p  0.05 to be signiﬁcant.
During the post-acute phase, a linear trend line was
calculated for each haematological parameter and animal.
The lines were ﬁtted using linear regression and the
signiﬁcance of the slope parameter (as being different from
0) established using a random permutation exact test.
Linear regression was also used to ﬁt lines to the post-acute
stage data by treatment status and presence/absence of
sequestra. Given the repeated measures nature of these
data it was not appropriate to statistically compare the
groups using linear regression; instead the slope parame-
ter of each line was compared using a random permutation
exact test.
Prior to analysis of antigen speciﬁc responses certain
adjustments were made to the data: day 0 was taken as
baseline, serum from a healthy control cow that had been
measured once in each of the runs was used to adjust
antigen speciﬁc antibody responses—any response less
than ‘average control animal response + 3.75 std. dev.’ was
set to 0 (3.75 is the 98% conﬁdence interval t-distribution
with 4 degrees of freedom value: median ﬂuorescence
intensities lying within this interval suggest a lack of
sensitivity in the antigen measurement tool and/or
represent a zero antibody response to this antigen). His-
tag responses were not considered in the analysis as they
represented a control indicating potential binding to the
tag and only 8 of the 221 sera tested were slightly above
the interval deﬁned above.
The overall proﬁle of antigen-speciﬁc antibody
responses over time, comparing presence/absence of
sequestra and treatment status, were analysed using a
repeated measures analysis of variance (ANOVA) for
response variables: total antigen response, average antigen
response (total response/number of antigens with
response > 0) and number of antigens responding. Signiﬁ-
cance of sequestra presence/absence, treatment status,
time and their interactions were evaluated by F-distribu-
tion p-values (0.05 = signiﬁcant) and least signiﬁcant
differences (l.s.d.) given in the ﬁgure legends to aid
interpretation. Residual checks were performed to conﬁrm
normality and independence.
Various methodologies were applied to look at the
performance of speciﬁc antigens and their relationship
with the presence/absence of sequestra and the treatment
status of animals: comparison of average response (over
E. Schieck et al. / Veterinary Microbiology 172 (2014) 285–293288time) for each antigen using a random permutation exact
test; simple ranking of average response (over time) of
each antigen for each animal and comparison of the
median ranking; combined ANOVA for all antigens of
average response (over time), natural log-transformed to
normalize, and the antigen ranking of this response—
residual checks done to conﬁrm normality and indepen-
dence; Principal Component Analysis (PCA), on the data
across time for each antigen and animal, to identify the
best independent linear combination of antigens that
described the variation in the data—‘sums of squares and
products’ method used and assumption made that
antigens respond on the same scale, implying that high
reacting antigens (and those with large variation) have a
major inﬂuence on the linear combinations for the top
principal components. The PCA was not used to compare
sequestra and treatment status, however graphical repre-
sentation is provided to aid interpretation of the results.
All analyses were carried out in GenStat 15.1 (VSN
International, 2012).
3. Results
3.1. Clinical observations
Infection was conﬁrmed in all animals by seroconver-
sion as shown by CFT and cELISA between 14 and 21 days
post infection (dpi) (Schubert et al., 2011).
Temperatures above 39 8C (deﬁned as fever in this
study) were recorded in all seven animals from day 2 pi
(Supplementary Fig. S1A). In ﬁve animals (BD104, BD108,
BD112, BD114 and BD117) the fever peaked between day 4
and day 7 pi with peak temperatures ranging from 40.8 8C
to 41.7 8C, accompanied by breathing distress, coughing,
temporal recumbency, and inappetence. Due to the
severity of the clinical symptoms these ﬁve animals were
treated with a single dose of oxytetracycline on day 7 pi
(BD114 and BD117) and on day 9 pi (BD104, BD108 and
BD112), respectively. Following treatment, minor ﬂuctua-
tions in temperature were recorded, however all ﬁve
animals had temperatures below 39 8C by day 17 pi. The
two remaining animals (BD103 and BD109) had fever
peaking on day 14 pi with a recorded temperature of 40.5
and 41.0 8C, respectively and their clinical course of disease
was less prominent. Without any treatment these animals
were fever free at 22 dpi. Throughout the remainder of the
study period, intermittent temperatures above 39 8C were
recorded in four animals (BD103, BD104, BD108 and
BD109), with animal BD108 showing more frequent and
higher fever peaks (Supplementary Fig. S1A).
3.2. Necropsy
All animals were euthanized between 232 and 234 dpi,
and a post mortem analysis was performed. All seven
animals had ﬁbrous adhesions (Table 1). Sequestra were
detected in two animals (BD103 and BD112), of which
BD112 received a single dose of oxytetracycline during the
acute stage of infection while BD103 did not receive any
antimicrobial treatment.
3.3. Microbiology
We have been able to cultivate Mmm only from
sequestra of animal BD103. All animals tested negative
for the presence of Pasteurella spp. and Mannheimia spp.
3.4. Detection of Mmm by PCR
A multiplex real-time PCR assay using lung tissue was
positive for two animals that had sequestra at postmortem
analysis (BD103 and BD112).
Table 1
Summary of clinical and pathological data.
Animal no. Clinical
symptoms
Treatment
with OTC
Pathomorphological ﬁndings PCR detection of
Mmm/Cultivation
of Mmm
Fibrous adhesions Sequestra
BD103 Fever No Right diaphragmatic
lung lobe
Three in right
diaphragmatic
lung lobe
Positive/positive
BD104 Cough, fever Day 9 Left diaphragmatic
lung lobe
Negative/negative
BD108 Cough, fever Day 9 Caudal end of the
right diaphragmatic
lung lobe
Negative/negative
BD109 Fever No Left diaphragmatic
lung lobe
Negative/negative
BD112 (female) Cough, fever Day 9 Caudal end of the
right diaphragmatic
lung lobe,
One in the caudal
end of right
diaphragmatic
lung lobe
Positive/negative
BD114 Cough, fever Day 7 Right diaphragmatic
lung lobe
Negative/negative
BD117 Cough, fever Day 7 Right diaphragmatic
lung lobe
Negative/negativeOTC—oxytetracycline; Mmm—Mycoplasma mycoides subsp. mycoides.
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None of the animals were positive for BHV-1, BHV-2
 Q-fever. All animals had antibodies to BRSV and PI-3,
ich did not coincide with the onset of CBPP or fever
ks observed during the course of CBPP (Supplementary
le S1).
 Haematology
In the acute stage i.e. between 1 dpi (ﬁrst recorded
er) and 22 dpi (end of initial fever episode) a signiﬁcant
rease in lymphocytes (p = 0.047) and increase in
nulocytes (p = 0.031) was observed in comparison to
 pre-infection stage (Supplementary Fig. S1B-E and
plementary Table S2). The mean lymphocyte counts
re generally low, even below the normal range for cattle
% of total white blood cells) (Sjaastad et al., 2010). At the
 of the acute stage the lymphocyte and granulocyte
nts approached pre-infection levels.
During the post-acute stage of infection i.e. the
ainder of the study period after day 22, a number of
od parameters changed signiﬁcantly as compared to the
-infection stage (Supplementary Figure S1 C & E, S2 and
plementary Table S2). There was no signiﬁcant
erences in any of these trends (increasing or decreas-
) between sequestra or treatment status except for
matocrit where treated animals showed a steeper
rease in levels during the post-acute phase compared to
-treated animals (p = 0.048).
To test if OTC treated and non-treated animals differ in
 haematological parameters, random permutation
ct tests were performed for each stage (data not
wn). Also animals harbouring sequestra were com-
ed to those that did not. The only slightly signiﬁcant
erences identiﬁed between treated and non-treated
mals were for lymphocytes during the pre-infection
e (p = 0.048), white blood cell count during the acute
e (p = 0.048) and haematocrit (p = 0.048) in the post-
te stage. No differences in the measured haematolo-
l parameters in those harbouring sequestra compared
hose that did not were observed.
 Antigen speciﬁc humoral immune responses
As expected, some antigens induced higher antibody
es than others (all median ﬂuorescence intensities
asured for all animals, time-points and antigens are
sented in Supplementary Table S3). Using PCA, the 10
igens explaining most of the variation and therefore
ing the largest positive or negative vectors in the ﬁrst
ee principal components in our 7 animals were proteins
rring to Mmm PG1 locus tags MSC_0079, MSC_0136,
C_0240, MSC_0390, MSC_0397, MSC_0431, MSC_0570,
C_0653, MSC_0813 and MSC_1046 (Supplementary
le S4). Overall, while global titres decreased over time,
 rank of the different speciﬁcities did not: the highest
ciﬁcities in the late chronic phase were the same as
se found in the acute or immediate post-acute phase.
The data also conﬁrmed that eight Mycoplasma antigens
cribed elsewhere as being suitable for a diagnostic test
(Neiman et al., 2009), were recognized by most animals
(and appear in the group identiﬁed using PCA), and in
many cases the antibody responses remained measurable
until the end of the study.
3.8. Antibody speciﬁcities and correlations with disease
outcomes
Correlations between the presence of particular anti-
body speciﬁcities and presence/absence of sequestra as
well as with antibiotic treatment/no treatment were
assessed. Any correlation between any particular antibody
speciﬁcity and a positive outcome on disease such as
reduced disease severity (i.e. no treatment), or absence of
sequestra would suggest the presence of a protective
antigen. We attempted to identify these antigens by
comparing the average response (over time) for each
antigen, using a random permutation exact test. A few
antigens showed borderline signiﬁcant differences (all
p = 0.048) in animals with treatment compared to those
without and in animals that developed sequestra com-
pared to those that did not. To ensure that we would not
miss any antigen speciﬁcity that would be interesting as a
vaccine candidate, and to conﬁrm the weakly signiﬁcant
ﬁndings from the random permutation exact test, we
extended our search for these antigen speciﬁcities by
ranking the average response to each antigen for each
animal and producing the median ranking for presence/
absence of sequestra and treatment status. The average
response (natural log transformed) and the median
ranking were then analysed using ANOVA. Although the
antigen speciﬁc responses were signiﬁcant in all cases
(p < 0.001 for all), indicating differing levels of responses,
no signiﬁcant interaction between the antigen speciﬁc
responses and presence/absence of sequestra (p = 0.991,
0.985 for loge response and rank, respectively) or
treatment status (p = 0.956, 0.347 for loge response and
rank, respectively) was observed. This means that the
differences in antibody levels between presence and
absence of sequestra or between treated and non-treated
animals did not alter depending on the antigen. Finally, we
used the important principal components from the PCA
analysis (principal component 1 and 2 combined account
for 81.6% of the variation in the data) to look visually at the
data (Supplementary Figure S3). In all these analyses, the
antigens identiﬁed in the random permutation exact test
did not appear to explain any difference between the
groups and therefore the exact test results could be
considered as representing the ‘5% of signiﬁcant results’
one would expect when conducting many comparisons.
Neither could any other antigen speciﬁc antibodies be
identiﬁed that would correlate with either persistence of
the pathogen (sequestra) or with antibiotic treatment.
3.9. Comparison of the quantitative humoral immune
response in animals with and without sequestra
Interestingly, two animals (BD103 and BD112) that had
sequestra had higher total antibody responses to the
antigens tested than the animals that did not harbour
sequestra (Fig. 1A). The difference was observed already
To
ta
l r
es
po
ns
e
Sequestra
No sequestra
10,000
20,000
30,000
40,000
50,000
Days post infection
28 2522241961681401128456
No treatment
Tetracycline
To
ta
l r
es
po
ns
e
5,000
45,000
15,000
25,000
35,000
200
400
600
800
1,000
1,200
1,400
1,600
1,800
A
ve
ra
ge
 re
sp
on
se
Sequestra
No sequestra
5
10
15
20
25
30
35
40
45
N
o 
of
 a
nt
ig
en
s 
re
sp
on
di
ng
Sequestra
No sequestra
No treatment
Tetracycline
A
ve
ra
ge
 re
sp
on
se
N
o 
of
 a
nt
ig
en
s 
re
sp
on
di
ng
No treatment
Tetracycline
A
FC
EB
D
10,000
20,000
30,000
40,000
50,000
5,000
45,000
15,000
25,000
35,000
200
400
600
800
1,000
1,200
1,400
1,600
1,800
Days post infection
28 2522241961681401128456
Days post infection
28 2522241961681401128456
Days post infection
28 2522241961681401128456
Days post infection
28 2522241961681401128456
Days post infection
28 2522241961681401128456
5
10
15
20
25
30
35
40
45
*
**
*
*
*
*
* *
*
*
***
**
*
*
*
**
*
*
*
*
*
*
*
*
* *
*
*
*
*
*
Fig. 1. Comparison of antibody responses in animals with sequestra vs. no sequestra and treated vs. non-treated (arbitrary units, mean ﬂuorescence
intensity, statistical method: repeated measures ANOVA). Signiﬁcant levels are marked (*p < 0.05). (A) Total antibody response to all measured antigens in
animals harbouring sequestra at the end of the study compared to those who did not. Least signiﬁcant difference: 11621.5. (B) Average antibody response
(total response divided by number of antigens) in animals harbouring sequestra at the end of the study compared to those who did not. Least signiﬁcant
difference: 571.3. (C) Total number of antigens that were recognized by animals harbouring sequestra at the end of the study compared to those who did
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 0.05) from 35 to 133 dpi. This difference remained
iﬁcant when the total response was divided by number
ntigens that the individual animals responded to, to
e an average response per antigen (Fig. 1B).
. Comparison of the number of antigens recognized in
mals with and without sequestra
To test whether the higher total antibody titres
erved in the animals harbouring sequestra were due
esponses to a larger number of antigens we counted the
ber of antigens to which there was any detectable
ponse (Fig. 1C). There was no signiﬁcant difference.
. Comparison of the quantitative humoral immune
onse in animals that were treated with oxytetracycline
 not treated
Five of the seven CBPP infected animals i.e. BD104,
08, BD112, BD114 and BD117, developed severe
ase at an early stage of the study and were therefore
ted with a single dose of oxytetracycline (OTC) at days
d 9 pi. Potential differences in the total and/or average
ibody response in OTC treated and non-treated animals
re investigated (Fig. 1D and E). There was no observable
erence between these groups. One of these animals still
boured sequestra at the end of the study (BD112) and as
cribed above had very high antibody titres, but this was
 true for the rest of the animals in the OTC treated
up.
. Comparison of the number of antigens recognized in
mals that were treated with oxytetracycline and not
ted
The possibility that the OTC treatment inﬂuenced the
come of the immune response by reducing the
hogen load was analysed. But also here, no difference
s observed between the number of antigens detected by
 sera from the OTC-treated and non-treated groups
. 1F).
iscussion
Cattle were challenged with aliquots of Mmm cultures
 the strain Afade´, stored at 80 8C for several months
t had successfully been used to infect cattle several
nths earlier (Sacchini et al., 2011). The storage of
coplasma culture aliquots at 80 8C enables the count-
 of colony forming units before infection and to more
dardize the infection model in the future. All seven
mals were successfully infected, since they developed
er with peak temperatures over 40 8C, they serocon-
ted and had typical symptoms of CBPP i.e. pneumonia,
including breathing distress (coughing), malnutrition/
inappetence and occasional recumbency.
As a consequence of the severe symptoms, ﬁve of the
seven cattle were treated with a single dose of oxytetra-
cycline (OTC). OTC has previously been reported to reduce
both clinical symptoms and the formation of sequestra in
cattle suffering from CBPP (Niang et al., 2010), however it
remains questionable if a complete clearance of the
bacteria can be achieved. The treatment rapidly brought
down the fever and all ﬁve animals survived. Fever in
treated (and non-treated) animals occasionally returned,
suggesting relapsing disease likely to be caused by
mycoplasma shed by individual animals such as BD103.
It is also right to assume that animals continued
transmitting mycoplasma, thereby re-infecting the
others. The OTC treatment did not result in any observable
differences in any of the parameters we measured
afterwards, and all animals had pathomorphological lung
lesions at post mortem while two animals, one treated
and the other not, had sequestra harbouring live (BD103)
and dead (BD112) Mycoplasma. Three out of the four
animals that had relapsing fever were negative for
Mycoplasma at the time of post mortem which suggests
total clearance of the pathogen in these animals at the
time of post mortem.
During the acute stage of disease, only few haemato-
logical parameters measured were signiﬁcantly different
from the pre-infection levels. A signiﬁcant decrease in
lymphocytes paired with a signiﬁcant increase in granu-
locytes was observed during the acute stage of disease. The
post acute clinical phase was characterized by animal to
animal variation in the parameters measured and at the
same time a signiﬁcant steady change in several haema-
tological parameters (Supplementary Fig. S1B, C, D, E and
Supplementary Fig. S2). The latter might be attributed to
the indoor housing and feeding conditions that were
different to the free roaming grazing conditions before
experimental infection.
The total antibody titres increased shortly after
challenge, peaking around one month post-infection,
dropping slowly afterwards. The role of antibodies in
protection to CBPP is not yet fully elucidated, but they are
likely to be important given the extracellular nature of the
pathogen. In this study, a signiﬁcant difference was found
between titres of animals that developed sequestra and the
ﬁve animals that fully cleared the infection. This difference
was apparent nearly over the whole study period from 14
dpi (Fig. 1A and B). No such difference was observed
between OTC-treated and non-treated animals, except for
a small difference in the period between one and two
months, although that difference was not statistically
signiﬁcant (Fig. 1D and E). When the total number of
mycoplasma antigens detected by the different sera was
compared between the groups, no differences were
observed between the animals with or without sequestra
(Fig. 1C) or between the OTC-treated or untreated groups
 Least signiﬁcant difference: 16.3. (D) Total antibody response to all measured antigens in animals that were treated with OTC compared to those who
e not. Least signiﬁcant difference: 18274.7. (E) Average antibody response (total response divided by number of antigens) in animals that were treated OTC compared to those who were not. Least signiﬁcant difference: 897.5. (F) Total number of antigens that were recognized by animals that were
ted with OTC compared to those who were not. Least signiﬁcant difference: 14.4.
E. Schieck et al. / Veterinary Microbiology 172 (2014) 285–293292(Fig. 1F). If antibody speciﬁcities characterized in this study
were critical in controlling the disease, one would expect
that animals with less severe pathological symptoms
would have higher antibody titres or/and would recognize
more antigens than animals with severe lesions. However,
our data do not show such correlations. On the contrary,
animals that demonstrably harboured mycoplasma until
the end of the study, i.e. those with sequestra, had the
highest antibody titres and did not detect a lower number
of antigens. Sequestra are likely to cause a persistent
leaking of antigen into the bloodstream, which would
trigger an antibody response. The latter needs to be
conﬁrmed by additional studies and does not explain the
early onset of signiﬁcant higher titres throughout most of
the experiment.
The correlation of higher titres and sequestra raises an
interesting question whether high titres might contribute
in one way or the other to pathology as indicated in
previous vaccination trials employing LppQ (Pilo et al.,
2007). The presence of vasculitis in CBPP (Thiaucourt et al.,
2004) might be caused by deposited antigen-antibody
complexes. To elucidate the presence of antigen-antibody
mediated vasculitis in CBPP is a challenge and requires
speciﬁc histopathological methods. We have also not been
able to pinpoint antibody speciﬁcities that correlate with
milder pathology nor with elimination of the pathogen
from the host. This suggests that antibodies directed
against the antigens tested here are not necessarily
important in controlling CBPP during a primary infection.
The fact that antibody titres or speciﬁcities investigated
here do not correlate with protection does not necessarily
mean that antibodies have no role in protection. First of all,
in this study, the critical protective antigens may not have
been present in our panel of mycoplasma antigens. For
example, we did not include non-proteinacious antigens
such as carbohydrates, which are known to exist in Mmm
(Bertin et al., 2013) and have been formulated in vaccines
against several diseases (Avci et al., 2013), in our panel of
antigens tested. Second, several immune responses may
work in tandem, and an innate mechanism may be more
important in control of disease during a primary challenge.
Third, antibodies may appear too late after infection to
have any measurable effect on protection. While anti-
bodies may be effective in preventing mycoplasma from
adhering to the host epithelial cells in the lungs or in killing
and/or removing them from the body, once the mycoplas-
ma have effectively attached to their target cell, antibodies
may no longer be effective. That implies that antibodies
may not be helpful during a primary infection, but would
be in a secondary infection when they can kill or remove
mycoplasma or prevent their attachment to host cells.
Such a scenario could also explain why immunity to CBPP
induced by a live vaccine wanes quickly after six to twelve
months, since total antibody titres and the number of
antigens recognized in this study tend to drop signiﬁcantly
over the seven month period of the experiment. One could
expect that this would also be the case after a live
vaccination. No speciﬁc antigen responses were observed
that correlated with the chronic phase of the infection.
Future efforts should include: (i) challenge of conva-
response, (ii) investigation of the role of other targets of the
humoral immune response (e.g. carbohydrates) and (iii)
transfer experiments to prove the hypothesis that a
humoral immune response is the protective arm of
immunity. A parallel empirical approach to develop a
better vaccine for CBPP has been demanded recently (Jores
et al., 2013).
5. Conclusion
It is possible to infect cattle with Mycoplasma mycoides
subsp. mycoides Afade´ culture aliquots that had been
stored at 80 8C for over 5 months. Therefore, the 80 8C
long-term storage of culture aliquots will enable stan-
dardization of the infectious agent in terms of the
determination of colony forming units before infection.
Animals that did not clear Mycoplasma from their system
seven months after infection had higher antibody titres
over most of the study time against part of the predicted
Mycoplasma surface proteome. This suggests a possible
role of high antibody titres in establishment of vasculitis or
that antibodies tested are ineffective in preventing disease.
Live Mycoplasma can be isolated from sequestra seven
months post infection as observed in one animal.
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